Mangoceuticals Inc (MGRX) 13F Filing Data & Analysis (Q2 2026)

Mangoceuticals (ticker: MGRX) and Nuclea Energy have mutually called off their business combination, less than a month after signing the deal on July 29, 2026. The sticking point was money: the agreement required at least $15 million in PIPE financing to be raised and placed in escrow before closing, and that funding never came through by the August 21 outside date. Both sides agreed to walk away, each covering its own costs, with mutual releases of claims — though liability for any willful breach still stands.

Mangoceuticals (MGRX) disclosed on August 4 that Nasdaq has granted it a second 180-day compliance period, now running until February 1, 2027, to fix the deficiency caused by its stock closing below $1.00 for 30 straight trading days. Nasdaq determined the company qualifies for the extension because it meets the other continued listing requirements, and Mangoceuticals said it will monitor the stock and may effect a reverse stock split if needed. The company also issued a press release referencing its recently announced business combination agreement with Nuclea Energy Inc.

Mangoceuticals (MGRX) has signed a Business Combination Agreement with Canada's Nuclea Energy to combine the two companies. Under the deal's exchangeable-share structure, former Nuclea shareholders would end up with roughly 96% of Mango's fully diluted equity, leaving existing Mango stockholders with about 4%. The transaction includes a minimum $15 million PIPE financing and major leadership changes: Sagar Sanghera would become Executive Chairman, Josef Freundorfer would take over as CEO, and current CEO Jacob Cohen would move to President. Closing is expected before shareholder and Nasdaq approvals are in hand, with a second stage unlocking the full exchange rights once approvals are obtained.

Mangoceuticals entered into a private placement subscription agreement on June 29, 2026, issuing shares to an accredited investor. The company claimed an exemption from registration for the issuance. Specific terms like the number of shares or investment amount are not detailed in this excerpt.